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Abstract
Photodynamic diagnosis based on 5-aminolevulinic acid-
induced protoporphyrin IX has been clinically applied 
in many fields based upon its evidenced efficacy and 
adequate safety. In order to establish a personalized 
medicine approach for treating gastric cancer patients, 
rapid intraoperative detection of malignant lesions 
has become important. Feasibility of photodynamic 
diagnosis using 5-aminolevulinic acid for gastric cancer 
patients has been investigated, especially for the 
detection of peritoneal dissemination and lymph node 
metastasis. This method enables intraoperative real-
time fluorescence detection of peritoneal dissemination, 
exhibiting higher sensitivity than white light observation 
without histopathological examination. The method 
also enables detection of metastatic foci within 
excised lymph nodes, exhibiting a diagnostic accuracy 
comparable to that of a current molecular diagnostics 
technique. Although several complicating issues still 
need to be resolved, such as the effect of tissue 
autofluorescence and the insufficient depth penetration 
of excitation light, this simple and rapid method has the 
potential to become a useful diagnostic tool for gastric 
cancer, as well as urinary bladder cancer and glioma.
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Core tip: To perform personalized treatment for gastric 
cancer, rapid intraoperative detection of malignant 
lesions is desirable. Photodynamic diagnosis based on 
5-aminolevulinic acid-induced protoporphyrin Ⅸ may 
help in this regard. This method enables intraoperative 
real-time fluorescence detection of peritoneal dis-
semination in gastric cancer patients, exhibiting 
higher sensitivity than white light observation without 
histopathological examination. The method also 
enables detection of metastatic foci within excised 
lymph nodes, exhibiting a diagnostic accuracy com-
parable to a current molecular diagnostics technique. 
This method has the potential to become a useful 
diagnostic tool for gastric cancer treatment.
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2016; 22(3): 1289-1296  Available from: URL: http://www.
wjgnet.com/1007-9327/full/v22/i3/1289.htm  DOI: http://dx.doi.
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INTRODUCTION
Personalized medicine has become a trending topic 
in the treatment of gastric cancer[1-3]. In order to 
apply an individualized therapeutic strategy for each 
patient with gastric cancer, a precise evaluation of 
the extent of disease progression is essential[4].
Recent advances in endoscopic technology have 
enabled the early detection of malignant lesions, 
allowing a subset of patients with early gastric 
cancer to undergo a curative endoscopic resection[5]. 
However, a large percentage of gastric cancer patients 
still require some sort of surgical intervention. 
Distal or total gastrectomy with appropriate lymph 
node dissection is usually performed as a radical 
procedure, but the quality of life of patients who 
have undergone radical gastrectomy is diminished to 
some extent[6]. A less invasive personalized surgery, 
avoiding unnecessary lymph node dissection and 
reduced gastric resection, might be possible if lymph 
node metastases could be detected preoperatively or 
intraoperatively[7].
On another front, patients with advanced gastric 
cancer are often excluded from radical gastrectomy 
because advanced gastric cancer with peritoneal 
dissemination usually requires chemotherapy rather 
than surgery[8,9]. Sensitive intraoperative detection 
of occult peritoneal dissemination might save such 
patients from unnecessary gastrectomy and lead to 
early induction of appropriate chemotherapy[10].
Photodynamic diagnostics is considered a potent 
candidate to fill these demands. Photodynamic 
diagnosis using 5-aminolevulinic acid (5-ALA-PDD) has 
been widely used clinically because of its adequate 
safety and efficacy[11,12]. 5-ALA is an intrinsic amino 
acid intimately involved with heme synthesis in nu-
cleated cells. Because cancer cells exhibit alterations 
of enzymatic activity in the heme synthetic pathway, 
exogenous administration of 5-ALA causes intracellular 
accumulation of a heme precursor, protoporphyrin IX 
(PpIX), in cancer cells[13]. Importantly, PpIX emits red 
light upon excitation with 405-nm blue-violet light, 
whereas 5-ALA is not fluorescent.
In the field of gastrointestinal cancer treatment, 
5-ALA-PDD has been used for the in vivo detection 
of peritoneal dissemination in patients with advanced 
gastrointestinal cancer[14-16]. In addition, the feasibility 
of using 5-ALA-PDD to detect lymph node metastases 
is now being validated in clinical trials[17,18]. Thus, the 
availability of 5-ALA-PDD is increasingly anticipated 
since there are no other cancer-specific fluorophores 
easily applicable to clinical use.
In this review, we cover recent topics related to 
the use of 5-ALA-PDD in gastric cancer, focusing on 
fluorescence diagnostic laparoscopy and intraoperative 
fluorescence detection of metastatic lymph nodes.
ACCUMULATION OF PPIX IN GASTRIC 
CANCER CELLS
Although the mechanism of PpIX accumulation 
in cancer cells is not entirely clear, alterations of 
enzymatic activities in the heme synthetic pathway, i.e. 
increased activity of porphobilinogen deaminase and 
decreased activity of ferrochelatase, are considered to 
be the primary cause[19]. Porphobilinogen deaminase 
is induced upon administration of exogenous 5-ALA, 
and the enzymatic activity is increased accordingly[20]. 
Ferrochelatase, which acts in the final step of heme 
synthesis, contains an iron-sulfur cluster that is 
inhibited by nitric oxide[21,22]. Since the concentration 
of nitric oxide is often increased in cancer cells by 
upregulation of the inducible form of nitric oxide 
synthase, ferrochelatase activity is suppressed in 
cancer cells[23,24].
In addition, recent in vitro studies with gastric 
cancer cell lines have revealed other molecules that 
might regulate 5-ALA-PDD efficacy in gastric cancer. 
Intracellular uptake of exogenously administered 5-ALA 
is mediated by a peptide transporter, PEPT-1/2, and 
extracellular efflux of 5-ALA-induced PpIX is mediated 
by ATP-binding cassette transporter G2 (ABCG2)[25,26]. 
Therefore, the expression levels of PEPT-1/2 and 
ABCG2 are likely to be closely involved in the efficacy 
of 5-ALA-PDD in gastric cancer.
Furthermore, mitochondrial ATP-binding cassette 
transporter B6 (ABCB6) was found to mediate 
cytoplasm-to-mitochondria transport of coproporphy-
rinogen Ⅲ, an intermediate metabolite of heme 
synthesis[27]. The effect of mitochondrial ABCB6 
expression on 5-ALA-PDD was shown in an in vitro 
study with gastric cancer cell lines[28]. The results 
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correlated well with those from a study with excised 
glioma tissues[29].
Thus, various molecular factors are involved in 
intracellular PpIX accumulation. A schematic of the 5-ALA 
metabolic pathway and intracellular PpIX accumulation 
in gastric cancer cells is shown in Figure 1.
PPIX FLUORESCENCE IN GASTRIC 
CANCER CELLS
PpIX emits red light with a peak at 635-nm upon 
excitation with 405-nm blue-violet light. Adding 5-ALA 
to the culture medium induces PpIX accumulation in 
cultured cancer cells. In vitro analysis of various types 
of gastric cancer cell lines has shown that treatment 
with 5-ALA and 405-nm excitation light induced the 
characteristic 635-nm PpIX fluorescence peak in all of 
the lines, with the fluorescence intensity dependent on 
the cell’s degree of differentiation (unpublished data) 
(Figure 2). This result strongly supports the notion that 
5-ALA-PDD is clinically applicable to gastric cancer.
5-ALA ADMINISTRATION TO GASTRIC 
CANCER PATIENTS AND MANAGEMENT 
OF 5-ALA-ADMINISTERED PATIENTS
In a clinical setting, 5-ALA is usually administered 
orally. In order to diminish its characteristic acidic taste, 
we have prepared and delivered it as a 50% glucose 
solution. Orally administered 5-ALA is rapidly absorbed 
in the upper gastrointestinal tract, and the plasma 
level of 5-ALA reaches a peak within 1 h after oral 
administration. At first, PpIX accumulation is observed 
in normal tissues, especially in the gastrointestinal 
mucosa, at 2-4 h after 5-ALA administration[30]. 
Thereafter, the accumulated PpIX in normal tissues 
is gradually metabolized, whereas PpIX accumulation 
in cancer cells is sustained for a while. After 6 h, the 
difference in PpIX concentrations between normal 
tissue and cancer tissue reaches its peak[13]. Thus, the 
timing of 5-ALA administration should be based on the 
estimated duration to fluorescence observation.
5-ALA is basically a safe substrate, also present 
in the human body. However, 5-ALA administration is 
contraindicated for patients with porphyria[31]. Since 
5-ALA is an initial chemical of porphyrin metabolism, 
high levels of 5-ALA in patients with porphyria lead 
to abnormal accumulation of various porphyrins, 
depending on the type of porphyria. This aberrance 
may cause phototoxic skin disorder, neurological 
dysfunction, and/or liver damage[32,33].
Gastric cancer patients with accompanying pyloric 
stenosis should also be excluded from 5-ALA-PDD since 
efficient absorption of 5-ALA is impossible. In addition, 
gastric cancer patients receiving certain antacid 
agents, such as histamine H2 receptor antagonists and 
proton pump inhibitors, should be excluded because 
5-ALA is unstable in high-pH conditions[34,35].
Patients who are administered photosensitizers 
should avoid unnecessary light exposure to reduce 
the risk of developing cutaneous photosensitivity. 
Other available photosensitizers, e.g., porfimer sodium 
(Photofrin) and talaporfin sodium (Laserphyrin), have 
a long serum half-life and thus necessitate longer-term 
protection from light exposure[36]. However, physicians 
need not be so diligent in the case of 5-ALA, since 
5-ALA-induced PpIX is metabolized to heme within a 
few hours[37].
We have performed 5-ALA-PDD for > 100 patients 
with gastrointestinal malignancies in clinical trials, and 
have observed no apparent adverse effects to date, 
including phototoxic skin disorder or liver dysfunction.
5-ALA-PDD FOR PERITONEAL 
DISSEMINATION IN GASTRIC CANCER 
PATIENTS
The efficacy of 5-ALA-PDD for detection of peritoneal 
dissemination has been demonstrated in a number 
of studies using animal models and in clinical 
trials[14,16,38-40]. In the treatment of gastric cancer, 
precise detection of occult dissemination is certainly 
important to select patients requiring chemotherapy 
and to pursue an improved prognosis[9]. Minute 
dissemination is sometimes undetectable by white 
light observation, and definitive diagnosis can only 
be achieved by histopathological examination of 
the excised specimen. In this regard, fluorescence 
observation is advantageous because it enables real-
time in vivo visualization without the need for time-
consuming histological examination.
A fluorescence laparoscopic system capable of 
providing 405-nm excitation light through a rigid 
laparoscope is now commercially available, and as 
a result diagnostic laparoscopy can be performed 
with minimal invasiveness. Figure 3 shows 5-ALA-
PDD images from a patient with advanced gastric 



















Figure 1  Metabolic pathway of 5-aminolevulinic acid and mechanism of 
intracellular protoporphyrin Ⅸ accumulation in gastric cancer cells.
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liver metastases could not be evaluated due to the 
insufficient penetration depth of the excitation light.
Regarding the diagnostic performance of 5-ALA-
PDD for peritoneal dissemination, Almerie et al[38] 
determined in a systematic review that the ranges of 
sensitivity and specificity were 83% to 100% and 95% 
to 100%, respectively[38]. The authors reported that 
cancer suspected to be accompanied by peritoneal 
dissemination. An intraperitoneal nodule exhibited 
red fluorescence (Figure 3A), indicating that it is a 
disseminated nodule, similar to a serosal invasion 
of the primary lesion (Figure 3B). 5-ALA-PDD also 
enabled a qualitative diagnosis of superficial liver 
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Figure 2  Fluorescence spectra of various kinds of gastric cancer cell lines after treatment with 5-aminolevulinic acid and excitation with 405-nm light. 
A: MKN-7, derived from a well differentiated gastric cancer; B: MKN-74, derived from a moderately differentiated gastric cancer; C: MKN-45, derived from a poorly 
differentiated gastric cancer; D: Kato-III, derived from a signet-ring cell carcinoma; E: NIH-3T3, a non-cancerous fibroblast-like cell line. Each cell line was incubated 
with 1 mmol/L 5-ALA for 30 min. The conditions of spectral acquisition were equivalent among all samples. Spectra were measured with the MCPD-7000 spectral 
analytical system (Otsuka Electronics, Co., Ltd., Osaka, Japan).
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Figure 3  Representative images of 5-aminolevulinic acid - photodynamic diagnosis. Upper column: White light images; Lower column: Fluorescence images. A: 
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5-ALA-PDD increased the detection rate of malignant 
peritoneal nodules by 21% to 34% over white light 
alone.
Detailed analyses of animal models and clinical trials 
have indicated satisfactory diagnostic performance 
of 5-ALA-PDD in gastric cancer[15,16,40]. Kishi et al[40] 
first validated the efficacy of 5-ALA-PDD by analyzing 
729 peritoneal nodules obtained from 8 mice. In that 
study, the detection rate with 5-ALA-PDD was 72%, 
which was significantly higher than that for the white 
light observation (39%). In addition, in a clinical trial 
for patients with advanced gastric cancer, Murayama 
et al[16] evaluated the availability of 5-ALA-PDD. 
The trial consisted of 13 patients, 5 of which were 
diagnosed with peritoneal dissemination by 5-ALA-
PDD. The diagnoses were confirmed by subsequent 
histopathological examination. Whereas 14 peritoneal 
nodules with suspected dissemination were detected 
under white light observation, only 12 nodules showed 
red fluorescence by 5-ALA-PDD. Histopathological 
examination indicated that only those 12 nodules were 
disseminated. Therefore, the diagnostic accuracy of 
5-ALA-PDD was concluded to be greater than that of 
white light imaging[16].
Furthermore, Kishi et al[15] demonstrated the 
usefulness of adding 5-ALA-PDD to conventional 
white light laparoscopy in another clinical trial with 
52 advanced gastric cancer patients. The authors 
reported that, using white light observation, 24 of 
the 52 patients showed no macroscopic evidence of 
peritoneal dissemination, but when 5-ALA-PDD was 
used dissemination was detected in 5 of these 24 
patients. Thus, the authors concluded that 5-ALA-PDD 
improved the sensitivity for the detection of peritoneal 
dissemination[15].
On the basis of these clinical trials, 5-ALA-PDD 
appears to be a useful and promising procedure for the 
detection of peritoneal dissemination. Future studies 
are needed, however, to determine whether the 
increased sensitivity leads to an improvement in the 
final outcome for patients who have undergone 5-ALA-
PDD.
5-ALA-PDD FOR LYMPH NODE 
METASTASIS OF GASTRIC CANCER
Limited operations with reduced lymph node dissection 
based on the sentinel node concept have recently 
attracted much attention in the field of gastric 
cancer surgery, similar to that in the field of breast 
cancer[41-43]. In performing sentinel node navigation 
surgery for gastric cancer, partial or segmental 
gastrectomy with limited lymphatic basin dissection is 
performed, and sustained post-gastrectomy quality of 
life can be provided[44].
However, in order to perform such procedures with 
adequate tolerability, a rapid and precise method is 
required to diagnose the presence or absence of lymph 
node metastases intraoperatively[45]. The existing 
intraoperative rapid histopathological diagnosis, which 
is based on frozen sections, has several liabilities. One 
is the amount of time required to make a histological 
section. Another liability is that minute metastases 
might not be detected due to the limited number 
of histological sections, resulting in a relatively high 
proportion of false-negatives[46].
To overcome these issues, we used 5-ALA-PDD 
for the detection of lymph node metastases of gastric 
cancer. Previously, Murayama et al[47] reported an 
excellent diagnostic accuracy (100% sensitivity 
and 100% specificity) of 5-ALA-PDD for detecting 
metastatic lymph nodes in a model mouse of rectal 
cancer. Building upon this finding, our group conducted 
a clinical trial with 14 patients with advanced gastric 
cancer, and examined a total of 144 lymph nodes[17]. 
Figure 4 shows representative 5-ALA-PDD images of 
metastases in resected lymph nodes. The metastatic 
lymph nodes exhibit a distinct red fluorescence con-
sistent with the distribution of a metastatic focus. 
Although some non-metastatic lymph nodes were also 
fluorescent, these nodes could be distinguished from 
metastasis-bearing lymph nodes by their characteristic 
follicular fluorescence pattern. Using a diagnostic 
algorithm for the fluorescence pattern, we found that 
5-ALA-PDD achieved an acceptable diagnostic power, 
with 92.4% accuracy (133/144).
Furthermore, we performed a quantitative analysis 
based on the nodules’ fluorescence intensities. 
Metastatic lymph nodes were significantly brighter 
than non-metastatic lymph nodes (P < 0.0001)[17]. 
Subsequent receiver operating characteristic analysis 
revealed 70.8% sensitivity and 94.4% specificity, with 
an area under the curve of 0.832. Although a sustained 
effort to improve the diagnostic sensitivity is required, 
future clinical application is strongly anticipated based 
on clinical results that will gradually accumulate in the 
near future.
Another innovative diagnostic method, the one-step 
nucleic acid amplification (OSNA) assay, has already 
been applied widely in the field of breast cancer[48]. 
OSNA is a new type of molecular diagnostic tool that 
is based on amplification of CK19 mRNA, which is 
expressed in metastasized foci within a lymph node[49]. 
The ability of OSNA to detect metastatic lymph nodes 
of gastric cancer has been evaluated; Yaguchi et al[50] 
reported a diagnostic accuracy of 96.6%. Yet, some 
obstacles remain: tissue contamination may cause false-
positive results, and low CK19 expression may lead 
to false-negatives[51]. The greatest obstacle, however, 
is that subsequent histological examination cannot 
be performed, because OSNA requires homogenized 
tissue specimens. In this regard, 5-ALA-PDD offers an 
advantage, since metastatic foci are visualized in non-
Koizumi N et al . Advances in 5-ALA-PDD of gastric cancer
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homogenized nodules.
FUTURE PROSPECTS
Although fluorescence diagnostics have many advan-
tages, the exclusion of background tissue autofluores-
cence remains a major unresolved issue and needs 
to be addressed in order to improve diagnostic 
accuracy. Surrounding connective tissues have their 
own autofluorescence, which sometimes interferes 
with the precise detection of PpIX red fluorescence. 
However, we attained highly sensitive detection of 
metastasized lymph nodes in patients with colorectal 
cancer by using the spectral unmixing method[18]. 
Specifically, we demonstrated an improved diagnostic 
performance of 5-ALA-PDD, with 88.3% sensitivity, 
92.0% specificity, and 87.4% accuracy. The receiver 
operating characteristic analysis revealed that the 
spectral unmixing method improved the area under 
the curve up to 0.95, indicating that the method might 
be an innovative solution.
Furthermore, we established a novel imaging 
strategy to specifically detect accumulated PpIX 
and filed an international patent application (WO/
2013/002350). Through such technical advances, we 
anticipate that we will be able to attain a satisfactory 
diagnostic accuracy of 5-ALA-PDD in the near feature.
The limited depth penetration of the excitation 
light is another issue that still needs to be addressed. 
Although the penetration is sufficient for the detection 
of peritoneal dissemination, detection of lymph 
node metastases requires cutting the nodes and 
performing fluorescence observation at the cut surface. 
In a study aiming to overcome this disadvantage, 
Shimoyama et al[52] showed the potential of the lan-
thanide nanoparticle, a light energy upconverter. 
The combination of optimal lanthanide nanoparticle 
and 5-ALA-PDD might allow the use of near-infrared 
excitation light, which can penetrate deeply into the 
tissue and result in better diagnostic accuracy.
CONCLUSION
We reviewed the recent advances in the use of 5-ALA-
PDD for the treatment of gastric cancer. Fluorescence 
diagnostics offer real-time visualization with high 
sensitivity unsurpassed by other diagnostic tools. With 
further technical development, application of 5-ALA-
PDD is expected to become more widespread in gastric 
cancer treatment.
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